EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Redefining Diagnostic and Management Approaches to Vancomycin Adverse Drug Reactions

Santiago Alvarez-Arango, Katherine C Konvinse, Manaswini Pujar, Ingrid P Salciccioli, Christopher M Bland, Kimberly G Blumenthal

The Journal of Allergy and Clinical Immunology: In Practice · 2026

DOI: 10.1016/j.jaip.2026.02.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026. Verfasst von Santiago Alvarez-Arango und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Department of Medicine and Pediatric, University of Texas Southwestern Medical Center, Dallas, Tex; Division of A…. Hauptthemen laut MEDLINE: Vancomycin, Drug Hypersensitivity, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, AAAAI Foundation, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vancomycin remains a cornerstone therapy for resistant gram-positive infections, yet adverse drug reactions are common and often mislabeled, leading to unnecessary avoidance and downstream negative consequences. This review summarizes the epidemiology, mechanisms, diagnostic tools, and management strategies to support mechanism-based care. Vancomycin infusion reaction, likely driven by Mas-related G-protein coupled receptor X2, is the most common vancomycin-induced hypersensitivity phenotype, whereas IgE-mediated reactions are rare and remain mechanistically unproven. Diagnostic limitations are substantial, because reactions can be clinically identical and distinguishing biomarkers or diagnostic tools are lacking. Dose-response intradermal testing for vancomycin infusion reaction evaluation is an emerging approach. Vancomycin infusion reaction management focuses on supportive therapy and adjustment of the infusion rate, whereas recurrent or severe reactions should prompt allergy evaluation for a possible IgE-mediated mechanism. Delayed reactions are less well characterized and span a spectrum from benign morbilliform eruptions to severe cutaneous adverse reactions, most notably drug reaction with eosinophilia and systemic symptoms. Diagnostic testing for delayed reactions remains limited, with no validated skin testing methods and in vitro assays restricted to research settings. Continued advances in understanding immunologic mechanisms, together with standardized electronic health record terminology and delabeling pathways, are essential to improve diagnostic accuracy and strengthen antimicrobial stewardship.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinDrug HypersensitivityAnti-Bacterial AgentsHumansGram-Positive Bacterial InfectionsImmunoglobulin EHypersensitivity, DelayedHypersensitivity, ImmediateDrug EruptionsSkin TestsReceptors, G-Protein-CoupledNerve Tissue ProteinsReceptors, Neuropeptide

Stichwörter der Autor:innen

Antibiotic allergyDelayed drug hypersensitivityDrug allergyDrug hypersensitivity reactionsDrug reaction with eosinophilia and systemic symptomsHuman leukocyte antigenImmediate drug hypersensitivityMRGPRX2Vancomycin infusion reaction

Substanzen

VancomycinImmunoglobulin EAnti-Bacterial AgentsMRGPRX2 protein, humanReceptors, G-Protein-CoupledNerve Tissue ProteinsReceptors, Neuropeptide

Autor:innen und Institutionen

  • Division of Allergy and Immunology, Department of Medicine and Pediatric, University of Texas Southwestern Medical Center, Dallas, Tex; Division of Allergy and Immunology, Department of Pediatrics, University of Texas S…
  • Division of Allergy and Immunology, Department of Pediatrics, Stanford University, Palo Alto, Calif.
  • Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass.
  • Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
  • Department of Administrative Pharmacy, University of Georgia College of Pharmacy, Savannah, Ga.
  • Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, Fla; The Mongan Institute, Massachusetts General Hospital, Boston, Mass.

Förderung

  • NIAID NIH HHS
  • AAAAI Foundation
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Alvarez-Arango, S., Konvinse, K. C., Pujar, M., Salciccioli, I. P., Bland, C. M., & Blumenthal, K. G. (2026). Redefining Diagnostic and Management Approaches to Vancomycin Adverse Drug Reactions. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2026.02.008

Vancouver

Alvarez-Arango S, Konvinse KC, Pujar M, Salciccioli IP, Bland CM, Blumenthal KG. Redefining Diagnostic and Management Approaches to Vancomycin Adverse Drug Reactions. The Journal of Allergy and Clinical Immunology: In Practice. 2026. doi:10.1016/j.jaip.2026.02.008

BibTeX
@article{AlvarezArango2026,
  author = {Alvarez-Arango, Santiago and Konvinse, Katherine C and Pujar, Manaswini and Salciccioli, Ingrid P and Bland, Christopher M and Blumenthal, Kimberly G},
  title = {Redefining Diagnostic and Management Approaches to Vancomycin Adverse Drug Reactions},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2026},
  doi = {10.1016/j.jaip.2026.02.008}
}
Kostenlos starten →